Literature DB >> 26756746

Cerebral β-Amyloid Angiopathy Is Associated with Earlier Dementia Onset in Alzheimer's Disease.

Eric D Vidoni1, Hung-Wen Yeh, Jill K Morris, Kathy L Newell, Abdulfattah Alqahtani, Nicole C Burns, Jeffrey M Burns, Sandra A Billinger.   

Abstract

BACKGROUND: Cerebral β-amyloid angiopathy (CAA) occurs when β-amyloid (Aβ) is deposited in the vascular media and adventitia. It is a common pathology in the brains of older individuals and has been linked to cognitive decline, but relatively little is known about the influence that CAA has on the clinical manifestation of Alzheimer's disease (AD). The aim of this retrospective analysis was to quantify the effect that CAA had on the manifestation of initial AD-related cognitive change and subsequent progression of dementia.
METHODS: We analyzed neuropathological data from the National Alzheimer's Coordinating Center's data set, performing parametric analyses to assess differences in age of progression to moderate-stage dementia.
RESULTS: We found that individuals with both CAA burden and Aβ neuritic plaque burden at death had the greatest risk of earlier conversion to very mild and moderate-stage dementia, but not necessarily faster progression.
CONCLUSIONS: Our results suggest that CAA contributes to changes in early AD pathogenesis. This supports the idea that vascular change and neuritic plaque deposition are not just parallel processes but reflect additive pathological cascades that influence the course of clinical AD manifestation. Further inquiry into the role of CAA and its contribution to early cognitive change in AD is suggested.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26756746      PMCID: PMC4915344          DOI: 10.1159/000441919

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  19 in total

1.  Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy.

Authors:  Gregory A Dierksen; Maureen E Skehan; Muhammad A Khan; Jed Jeng; R N Kaveer Nandigam; John A Becker; Ashok Kumar; Krista L Neal; Rebecca A Betensky; Matthew P Frosch; Jonathan Rosand; Keith A Johnson; Anand Viswanathan; David H Salat; Steven M Greenberg
Journal:  Ann Neurol       Date:  2010-10       Impact factor: 10.422

Review 2.  Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests.

Authors:  K A Bates; G Verdile; Q-X Li; D Ames; P Hudson; C L Masters; R N Martins
Journal:  Mol Psychiatry       Date:  2008-09-16       Impact factor: 15.992

3.  Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions.

Authors:  Sylvia Villeneuve; Bruce R Reed; Cindee M Madison; Miranka Wirth; Natalie L Marchant; Stephen Kriger; Wendy J Mack; Nerses Sanossian; Charles DeCarli; Helena C Chui; Michael W Weiner; William J Jagust
Journal:  Neurology       Date:  2014-06-06       Impact factor: 9.910

4.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

Authors:  M Shibata; S Yamada; S R Kumar; M Calero; J Bading; B Frangione; D M Holtzman; C A Miller; D K Strickland; J Ghiso; B V Zlokovic
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

Review 5.  Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy.

Authors:  Roy O Weller; Delphine Boche; James A R Nicoll
Journal:  Acta Neuropathol       Date:  2009-02-22       Impact factor: 17.088

6.  Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

Authors:  D Boche; E Zotova; R O Weller; S Love; J W Neal; R M Pickering; D Wilkinson; C Holmes; J A R Nicoll
Journal:  Brain       Date:  2008-10-25       Impact factor: 13.501

7.  High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

Authors:  Paul S Aisen; Lon S Schneider; Mary Sano; Ramon Diaz-Arrastia; Christopher H van Dyck; Myron F Weiner; Teodoro Bottiglieri; Shelia Jin; Karen T Stokes; Ronald G Thomas; Leon J Thal
Journal:  JAMA       Date:  2008-10-15       Impact factor: 56.272

Review 8.  Role of vascular risk factors and vascular dysfunction in Alzheimer's disease.

Authors:  Dara L Dickstein; Jessica Walsh; Hannah Brautigam; Steven D Stockton; Samuel Gandy; Patrick R Hof
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb

Review 9.  Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain.

Authors:  Dietmar Rudolf Thal; Lea Tenenholz Grinberg; Johannes Attems
Journal:  Exp Gerontol       Date:  2012-06-13       Impact factor: 4.032

10.  Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly.

Authors:  Prashanthi Vemuri; Timothy G Lesnick; Scott A Przybelski; David S Knopman; Greg M Preboske; Kejal Kantarci; Mekala R Raman; Mary M Machulda; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Walter A Rocca; Rosebud O Roberts; Ronald C Petersen; Clifford R Jack
Journal:  Brain       Date:  2015-01-15       Impact factor: 13.501

View more
  7 in total

1.  Dynamics of middle cerebral artery blood flow velocity during moderate-intensity exercise.

Authors:  Sandra A Billinger; Jesse C Craig; Sarah J Kwapiszeski; Jason-Flor V Sisante; Eric D Vidoni; Rebecca Maletsky; David C Poole
Journal:  J Appl Physiol (1985)       Date:  2017-03-09

2.  Brain arterial dilatation and the risk of Alzheimer's disease.

Authors:  Jose Gutierrez; Vanessa Guzman; Farid Khasiyev; Jennifer Manly; Nicole Schupf; Howard Andrews; Richard Mayeux; Adam M Brickman
Journal:  Alzheimers Dement       Date:  2019-03-01       Impact factor: 21.566

3.  Innate Immunity Stimulation via Toll-Like Receptor 9 Ameliorates Vascular Amyloid Pathology in Tg-SwDI Mice with Associated Cognitive Benefits.

Authors:  Henrieta Scholtzova; Eileen Do; Shleshma Dhakal; Yanjie Sun; Shan Liu; Pankaj D Mehta; Thomas Wisniewski
Journal:  J Neurosci       Date:  2017-01-25       Impact factor: 6.167

4.  Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine?

Authors:  Jian-Ming Li; Li-Ling Huang; Fei Liu; Bei-Sha Tang; Xiao-Xin Yan
Journal:  BMC Neurol       Date:  2017-08-25       Impact factor: 2.474

5.  Absence of microglia promotes diverse pathologies and early lethality in Alzheimer's disease mice.

Authors:  Sepideh Kiani Shabestari; Samuel Morabito; Emma Pascal Danhash; Amanda McQuade; Jessica Ramirez Sanchez; Emily Miyoshi; Jean Paul Chadarevian; Christel Claes; Morgan Alexandra Coburn; Jonathan Hasselmann; Jorge Hidalgo; Kayla Nhi Tran; Alessandra C Martini; Winston Chang Rothermich; Jesse Pascual; Elizabeth Head; David A Hume; Clare Pridans; Hayk Davtyan; Vivek Swarup; Mathew Blurton-Jones
Journal:  Cell Rep       Date:  2022-06-14       Impact factor: 9.995

Review 6.  The neuropathological diagnosis of Alzheimer's disease.

Authors:  Michael A DeTure; Dennis W Dickson
Journal:  Mol Neurodegener       Date:  2019-08-02       Impact factor: 14.195

7.  Reliability of P3 Event-Related Potential During Working Memory Across the Spectrum of Cognitive Aging.

Authors:  Hannes Devos; Jeffrey M Burns; Ke Liao; Pedram Ahmadnezhad; Jonathan D Mahnken; William M Brooks; Kathleen Gustafson
Journal:  Front Aging Neurosci       Date:  2020-10-19       Impact factor: 5.750

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.